Last updated: July 28, 2026
ecutive summary
The record for Bristol-Myers Squibb Company v. Synthon BV, 1:24-cv-00780 is not provided. A complete litigation summary and patent-focused analysis cannot be generated without the complaint/docket filings and the asserted patents (Orange Book identifiers, claims, and relief sought).
Litigation summary and analysis for Bristol-Myers Squibb Company v. Synthon BV | 1:24-cv-00780
What patents are asserted in BMS v. Synthon (1:24-cv-00780) and what claims are at issue?
Answer (required to start analysis): Not available in the provided materials.
Which Orange Book-listed patents typically drive this case?
Not available in the provided materials.
Are the asserted patents process, formulation, or method-of-use?
Not available in the provided materials.
What is the procedural posture in 1:24-cv-00780 (motions, claim construction, or trial scheduling)?
Answer: Not available in the provided materials.
Has the court set a Markman date?
Not available in the provided materials.
Has there been an injunction request or preliminary relief briefing?
Not available in the provided materials.
What Paragraph IV certifications and FDA filing details are alleged?
Answer: Not available in the provided materials.
Which BMS product is covered and what dosage form is implicated?
Not available in the provided materials.
Is the challenge to a ANDA, 505(b)(2), or other pathway?
Not available in the provided materials.
How does BMS frame infringement for Synthon BV (direct, induced, or contributory)?
Answer: Not available in the provided materials.
What does BMS allege about Synthon’s product composition or labeling?
Not available in the provided materials.
Does BMS plead design-around theories?
Not available in the provided materials.
How does Synthon respond (invalidity grounds, non-infringement, and equitable defenses)?
Answer: Not available in the provided materials.
What invalidity arguments are used (102/103, 112, or statutory bars)?
Not available in the provided materials.
Are there inequitable conduct or patent misuse allegations?
Not available in the provided materials.
What is the litigation timeline for 1:24-cv-00780?
Answer: Not available in the provided materials.
Filing and service dates
Not available in the provided materials.
Responsive pleading dates
Not available in the provided materials.
Claim construction and expert schedule milestones
Not available in the provided materials.
What is the potential outcome range and settlement leverage in 1:24-cv-00780?
Answer: Not available in the provided materials.
Likelihood of an injunction versus damages-only posture
Not available in the provided materials.
Relative strength indicators (primary patent scope, prior art density, and claim clarity)
Not available in the provided materials.
What generic entry risks exist for Synthon if BMS wins or loses?
Answer: Not available in the provided materials.
Entry trigger points (court decision date versus FDA exclusivity and patent expiry)
Not available in the provided materials.
Design-around options and label carve-outs
Not available in the provided materials.
How does this case compare with other BMS v. generics disputes?
Answer: Not available in the provided materials.
Are similar claims appearing across multiple defendants?
Not available in the provided materials.
Are there common invalidity themes?
Not available in the provided materials.
Key Takeaways
- A litigation summary and patent validity/infringement analysis for Bristol-Myers Squibb Company v. Synthon BV (1:24-cv-00780) cannot be produced from the information provided.
- Critical inputs that determine legal and competitive conclusions are absent: asserted patent numbers, FDA filing details, procedural posture, and docket milestones.
FAQs
- What patents does BMS assert in 1:24-cv-00780, and what do the asserted claims cover?
- What FDA filing (ANDA or 505(b)(2)) underlies the Paragraph IV dispute in this case?
- Has the court issued any substantive rulings (eligibility, claim construction, or infringement/non-infringement findings)?
- Does Synthon challenge the asserted patents as invalid under 35 U.S.C. §§ 102, 103, or 112?
- What is the fastest realistic generic entry scenario if BMS does not obtain an injunction?
References
- Not available from the provided prompt.
